Immunomedics Announces Preclinical Study Showed Epratuzumab's B-Cell Modulation Effect Elucidated
Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.